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High-throughput genomic technologies have identified biomarkers and potential therapeutic targets for 
ovarian cancer. Comprehensive functional validation studies of the biological and clinical implications of 
these biomarkers are needed to advance them toward clinical use. Amplification of chromosomal region 
5q31–5q35.3 has been used to predict poor prognosis in patients with advanced stage, high-grade serous ovar-
ian cancer. In this study, we further dissected this large amplicon and identified the overexpression of FGF18 
as an independent predictive marker for poor clinical outcome in this patient population. Using cell culture 
and xenograft models, we show that FGF18 signaling promoted tumor progression by modulating the ovar-
ian tumor aggressiveness and microenvironment. FGF18 controlled migration, invasion, and tumorigenicity 
of ovarian cancer cells through NF-κB activation, which increased the production of oncogenic cytokines and 
chemokines. This resulted in a tumor microenvironment characterized by enhanced angiogenesis and aug-
mented tumor-associated macrophage infiltration and M2 polarization. Tumors from ovarian cancer patients 
had increased FGF18 expression levels with microvessel density and M2 macrophage infiltration, confirming 
our in vitro results. These findings demonstrate that FGF18 is important for a subset of ovarian cancers and 
may serve as a therapeutic target.
Introduction
Epithelial ovarian cancer is the fifth leading cause of cancer-related 
death among women and has the highest case-fatality rate among 
gynecologic cancers. In the United States, approximately 22,280 
new cases and 15,500 deaths from ovarian cancer were estimated 
for 2012 (1). Serous tumors comprise about 70% of primary epi-
thelial ovarian cancer, with epithelial cells resembling those of the 
fallopian tube. Although there has been an improvement in the 
5-year survival rate for patients diagnosed with advanced disease, 
the long-term survival rate remains at 30% (2).
Due to insufficient power of clinicopathological features and 
traditional molecular predicators of outcome for serous ovar-
ian cancer, high throughput technologies such as comparative 
genomic hybridization (CGH) and gene expression profiling have 
been proposed for identifying gene signatures or signaling path-
ways as clinically relevant diagnostic and prognostic biomarkers 
(3–6). Comprehensive functional validation studies on both bio-
logical and clinical levels are needed to understand the mecha-
nistic basis for these biomarkers and to realize their full clinical 
significance and application.
In our previous study, oligonucleotide array CGH analysis on 
microdissected high-grade, advanced-stage serous ovarian tumor 
samples demonstrated the amplification of chromosome segment 
5q31 to 5q35.3 as one of the most significant copy number abnor-
malities associated with poor overall survival (4). To identify can-
didate genes that drive tumorigenesis in this aberrantly amplified 
chromosome segment, genes located between 5q31 and 5q35.3 were 
compared with a prognostic gene expression signature generated by 
expression profiling in an additional series of 53 microdissected 
high-grade, advanced-stage serous ovarian tumor samples (5). 
FGF18 (located on chromosome 5q35.1) was identified as the gene 
possessing the strongest prognostic value in segment 5q31–5q35.3, 
making it a suitable candidate for further characterization.
FGF18 is a highly conserved (99% amino acid identity among 
human, mouse, and rat), 21.2-kDa glycosylated secretory protein. 
FGF18 shows a structural similarity to FGF8 and FGF17, but is 
distinct from the most commonly studied FGF1 and FGF2. Tar-
geted disruption of FGF18 in mice is lethal beyond birth due to 
impaired skeleton development and alveologenesis, but Fgf1/Fgf2 
double-knockout mice are fertile without any gross phenotypic 
defects (7, 8), suggesting unique roles of FGF18 in both embryonic 
and postnatal development. Acting as a mitogenic, chemotactic, 
and angiogenic factor, FGF18 is required for the development of 
bone, cartridge, hair, cardiovasculature, and alveolus (8–11). Nev-
ertheless, the function of FGF18 has never been studied in the con-
text of serous ovarian cancer.
In this study, we have demonstrated that FGF18 is upregulated in 
serous ovarian tumors compared with normal ovarian surface epi-
thelium (OSE) by quantitative RT-PCR (qRT-PCR) and immuno-
histochemical (IHC) staining. In addition, increased expression 
of FGF18 mRNA and protein is associated with poor overall 
survival in patients. Ectopic expression and knockdown experi-
ments confirmed the pronounced oncogenic effect of FGF18 on 
tumor growth and metastasis. Further analysis revealed the effect 
of FGF18 on angiogenesis and tumor-associated macrophages 
(TAMs) in vitro and in vivo. Furthermore, FGF18 expression mark-
edly correlated with increased tumor microvessel density and TAM 
infiltration in samples from serous ovarian cancer patients. There-
fore, FGF18 plays important roles in promoting tumor progres-
sion by modulating the activity of both tumor cells and the tumor 
microenvironment and may serve as a potential therapeutic target.
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Results
FGF18 predicts survival in patients with high-grade, advanced-stage serous 
ovarian cancer. In the expression profiling data set generated by 
Mok et al. (5), with 53 microdissected, high-grade, advanced-stage 
serous ovarian adenocarcinoma samples, FGF18 possessed the 
highest prognostic potential by COX regression analysis among 
genes located in chromosome segment 5q31–5q35.3. Amplifi-
cation of this chromosomal segment strongly associated with 
poor outcome in serous ovarian cancer patients (4). Kaplan-
Meier analysis of the same 53 samples with median cut and log-
rank test showed a significant difference in overall survival time 
(P = 0.0002), with a Cox hazard ratio of 3.277 (P = 0.0003, 95% 
CI: 1.671–6.425), linking FGF18 with poor prognosis (Figure 
1A, estimated mean and median survival listed in Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI70625DS1). To ascertain whether expression of 
FGF18 might be contributing toward ovarian tumorigenesis, the 
53 high-grade serous cancer (HGSC) specimens were compared 
with 10 normal OSE brushings. FGF18 was upregulated 4.1-fold 
in serous ovarian tumor samples (Figure 1B, cumulative inten-
sity of all probe sets, P = 8.7 × 10–7, t test). The level of FGF18 in 
nonserous ovarian cancers was also investigated using available 
Figure 1
Identification of FGF18 as a prognostic gene in high-grade advanced-stage papillary serous ovarian tumors. (A) Kaplan-Meier analysis of FGF18 
expression in patients in 3 independent sets of serous ovarian cancer samples (Mok et al., ref. 5; Spentzos et al., ref. 3, and TCGA Project, ref. 6). 
Analysis was done by median cut with the P value of log-rank test presented for each set. Black lines, samples with low FGF18; red broken lines, 
samples with high FGF18; +, censored samples. (B) Overexpression of FGF18 in ovarian HGSC (n = 53) over normal OSE (n = 10) and FTE 
(n = 24). Array data import and normalization were performed by BRB array tools 4.1 with JustRMA algorithm. Values on y axis represent the 
cumulative intensity of all FGF18 probe sets. (C) CGH analysis of 72 serous ovarian tumors showed an increased DNA copy number for chromo-
some segment 5q31.3–5q35.3 in approximately 25% of the samples (upper panel). Chromosome 5 profiles of 2 representative tumors with the 
detail of a 7.3-Mb locus (chromosome 5 distance: 170.3 Mb–177.6 Mb) containing FGF18 and FGFR4 (lower panel). Copy number was presented 
by log2 minus 1 (value of 0 mean diploid, 1 mean 4 copies, 2 mean 8 copies). FGF18 and FGFR4 are amplified to at least 4 copies among the 
5615 probes in the x axis. (D) qPCR correlation with array CGH data for all 60 available DNA samples of the 72 serous tumors. Average qPCR 
fold changes were generated by 3 independent primer sets for FGF18 and FGFR4. Correlation was checked by Spearman’s ρ test.
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expression array data sets by comparing the sum intensity of all 
probe sets corresponding to FGF18. In a data set consisting of 41 
serous, 37 endometrioid, 13 mucinous, 8 clear cell ovarian carci-
nomas, and 4 individual normal ovary samples (12), significant 
upregulation of FGF18 was found in both serous and clear cell 
subtypes compared with normal ovarian tissue (1.77- and 1.87-
fold, P = 0.001 and 0.014 respectively). In contrast, no significant 
FGF18 upregulation was observed in mucinous and endometrioid 
subtypes (1.18- and 1.32-fold, P = 0.156 and 0.216 respectively). 
Moreover, in this cohort, the FGF18 level in serous tumors was 
considerable higher than that in mucinous tumors (P = 0.010) and 
endometrioid tumors (P = 0.050), but showed no significant dif-
ference from clear cell tumors (P = 0.829) (Supplemental Figure 
1A). Consistently, the significant upregulation of FGF18 in clear 
cell ovarian carcinoma was also demonstrated in another data set 
consisting of 10 microdissected clear cell ovarian carcinomas and 
10 normal OSEs (13) (7.75-fold, P = 0.044) (Supplemental Figure 
1B). Therefore, the upregulation of FGF18 in epithelial ovarian 
cancer may be histotypically specific rather than a general neoplas-
tic event. Nevertheless, considering the relatively low frequency of 
nonserous ovarian cancers (<30%), annotated data is not available 
for investigating the effect of FGF18 expression on clinical param-
eters in nonserous ovarian cancers. We thus focus the function of 
FGF18 in serous ovarian cancer in this work.
In addition to normal ovarian epithelium, FGF18 showed a 
likewise overexpression in HGSC over normal fallopian tube epi-
thelium (FTE), an alternative precursor of serous ovarian cancer 
(14, 15). In an independent 
data set consisting of 24 
microdissected normal FTEs, 
6 fallopian HGSCs and 7 
ovarian HGSCs (14), FGF18 
upregulation over normal 
FTEs was demonstrated 
in the 13 HGSCs (3.7-fold, 
P = 0.013) or 7 ovarian 
HGSCs (4.9-fold, P = 0.003). 
We further compared the 
FGF18 level in the 24 FTE 
samples with the 53-tumor 
panel, since both data sets 
were based on the same array 
platform (Affymetrix Human 
Genome U133 Plus 2.0). In 
this comparison, FGF18 
showed a 5.1-fold overex-
pression in the 53 ovar-
ian HGSCs over the 24 FTEs 
(P = 4.3 × 10–9) (Figure 1B). 
Finally, among the 18 mem-
bers of the human FGF fam-
ily proteins and 4 FGF recep-
tors, FGF18 was the only gene 
showing both tumor-related 
upregulation and strong cor-
relation with poor prognosis 
in the 53-tumor panel (Table 
1), suggesting a potentially 
unique role for FGF18 in 
ovarian tumorigenesis.
In order to validate the microarray data, qRT-PCR for FGF18 
was performed on 45 available RNA samples from the 53-tumor 
panel and 6 normal OSE, confirming the overexpression of FGF18 
in tumor tissue (3.9-fold, P = 4.1 × 10–5, t test). Survival analysis 
was done in a fashion analogous to the microarray analysis. A 
nonparametric log rank test (by median cut, P = 0.021) as well as 
COX regression analysis (P = 0.004) showed a significant survival 
difference and confirmed the microarray data. Analysis of anoth-
er independent data set of 70 epithelial ovarian cancer patients 
(3), also showed a significant prognostic value of FGF18 through 
Kaplan-Meier analysis (median cut, log-rank test, P = 0.026, Fig-
ure 1A) with a Cox hazard ratio of 2.023 (P = 0.0283; 95% CI: 
1.064–3.844). Finally, similar results were obtained by analyzing 
The Cancer Genome Atlas data set (6), in which FGF18 showed a 
1.72-fold upregulation (P = 3.35 × 10–9) compared with the 8 nor-
mal samples. Given the overall low intensity of the probe sets cor-
responding to FGF18, we used Kaplan-Meier analysis to compare 
the outcomes of patients in the highest and lowest 20% for FGF18 
expression in a group of 494 women with serous ovarian cancer. 
We observed a significant association of FGF18 with poor over-
all survival (log-rank test P = 0.019, Figure 1A; Cox hazard ratio: 
1.612; P = 0.0194; 95% CI: 1.076–2.415).
To further confirm the amplification of the FGF18 gene in 
serous ovarian cancer patients, array CGH analysis was performed 
on an independent cohort of 72 patients from Massachusetts Gen-
eral Hospital (MGH) between the years 1991 and 2008 (ref. 16 and 
Figure 1C and Supplemental Figure 2). Compared with the previ-
Table 1
Prognostic power of human FGF ligands and receptors
Probe set  Gene  53 HGSC/10 OSE 53 HGSC/24 FTE Cox regression 
(Affymetrix) name Fold P value Fold P value Score P value
205117_at FGF1 –8.92 0.006 2.54 1.83 × 10–15 0.261 0.609
204422_s_at FGF2 –4.00 1.60 × 10–5 –33.45 1.17 × 10–10 2.275 0.131
214571_at FGF3 2.91 0.034 1.58 0.122 0.170 0.68
206783_at FGF4 1.47 0.209 2.86 0.035 0.100 0.752
210311_at FGF5 1.10 0.658 1.52 2.25 × 10–9 0.453 0.443
208417_at FGF6 1.77 0.009 2.12 1.81 × 10–23 1.832 0.192
205782_at FGF7 –1.72 0.016 –4.14 9.33 × 10–4 0.109 0.742
208449_s_at FGF8 1.85 4.90 × 10–5 –1.55 6.17 × 10–5 0.005 0.945
239178_at FGF9 –4.62 0.003 –1.58 0.097 4.041 0.044
231762_at FGF10 –1.03 0.915 1.52 1.89 × 10–7 0.837 0.363
221374_at FGF16 1.71 0.016 2.25 1.57 × 10–22 0.634 0.426
221376_at FGF17 1.19 0.466 1.24 0.001 0.057 0.811
231382_at FGF18 5.00 6.00 × 10–9 20.42 2.06 × 10–10 16.33 5.30 × 10–5
223761_at FGF19 2.74 0.001 1.51 7.69 × 10–6 0.072 0.788
220394_at FGF20 –1.47 0.196 –1.2 0.009 0.408 0.523
221433_at FGF21 1.65 0.056 1.2 2.58 × 10–4 1.608 0.205
1566814_at FGF22 2.51 0.01 6.35 6.92 × 10–22 0.932 0.334
221166_at FGF23 1.94 0.02 2.94 3.97 × 10–21 1.762 0.18
226705_at FGFR1 –1.13 0.385 –2.58 8.83 × 10–7 1.561 0.212
203638_s_at FGFR2 2.39 0.003 –2.22 3.43 × 10–4 3.391 0.066
204379_s_at FGFR3 2.79 0.021 –8.70 1.03 × 10–5 1.598 0.206
204579_at FGFR4 1.38 0.106 2.25 2.62 × 10–14 0.985 0.321
Unique prognostic significance of FGF18 among the FGF/FGFR family members in serous ovarian cancer. Prognos-
tic power of the 18 human FGF ligands (FGF1–10, FGF16–23) and 4 FGF receptors in the 53 microdissected ovar-
ian HGSCs by univariate COX regression analysis. Comparison of the expression levels of these FGF ligands and 
receptors in the 53 HGSCs and normal tissues (10 OSEs or 24 FTEs) was also shown by the average fold-change 
and the corresponding P value (by Student’s t test). Only the probe set showing the highest intensity was listed for 
each gene. Boldface text highlights the unique prognostic power of FGF18 among the FGF/FGFR genes.
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ous study (4), a similar rate of 5q31.3–5q35.3 amplification was 
observed in approximately 25% of the patients and an average copy 
number of 4 was shown in both FGF18 and its potential receptor 
FGFR4 (located in chromosome 5q35.2, Figure 1C and Supple-
mental Figure 2). This observation was further validated by qPCR 
analysis correlating the amplification of FGF18/FGFR4 loci with 
CGH copy number (Figure 1D).
To test the prognostic value of FGF18 protein levels in serous 
ovarian cancer, IHC was performed in an independent formalin-
fixed, paraffin-embedded–based (FFPE-based) tissue microarray 
consisting of 47 benign ovarian cysts and 209 high-grade, 
advanced-stage ovarian serous adenocarcinomas with overall sur-
vival data. FGF18 protein staining intensity increased from low in 
benign cysts to strongly positive in a subset of high-grade tumors 
(1.98-fold, P < 0.0001) (Figure 2, A–E). In addition, Kaplan-Meier 
analysis correlating FGF18 staining intensity with overall patient 
survival demonstrated significant prognostic power of FGF18 as 
a marker of poor outcome (Figure 2F, Cox hazard ratio: 1.742; 
P = 0.0017; 95% CI: 1.226–2.474).
From the 209 samples on the tissue array, we have retrieved 
192 samples with clinical annotation of the debulking status, 
tumor grade (2 or 3), and FIGO tumor stage (III or IV). Univari-
ate Kaplan-Meier analysis of these 192 samples revealed signifi-
cant impact on patient overall survival from the FGF18 level (Cox 
hazard ratio: 1.941; P = 0.0003; 95% CI: 1.344–2.803), debulking 
surgery (Cox hazard ratio: 1.457; P = 0.071; 95% CI: 0.966–2.199), 
and tumor FIGO stage (Cox hazard ratio: 1.975; P = 0.002; 95% CI: 
1.268–3.078), but not the tumor grade (Cox hazard ratio: 0.816; 
P = 0.423; 95% CI: 0.493–1.349) (Supplemental Figure 3). Multi-
variate analysis through Cox regression model with all 4 parame-
ters (FGF18 level, debulking status, FIGO stage, and tumor grade) 
demonstrated the independent prognostic significance of FGF18 
(hazard ratio: 2.332; P = 0.00004; 95% CI: 1.558–3.491), which is 
not linked to known prognostic factors such as debulking status 
and FIGO stage (Supplemental Table 2). Similarly, the prognostic 
significance of FGF18 on overall survival was also demonstrated 
through Kaplan-Meier analysis after adjusting debulking status 
(P = 0.0013, Supplemental Figure 4A and Supplemental Table 3) 
and FIGO stage (P = 0.0001, Supplemental Figure 4B) (unadjusted 
P = 0.0003, log-rank test). Moreover, to avoid the subjectivity of 
cut-off selection, we also viewed the FGF18 IHC score as a continu-
ous variant for Cox regression analysis. Statistical significance for 
FGF18 as a prognostic factor was observed in univariate analysis 
(P = 0.0071) as well as multivariate analysis adjusted for debulking 
(P = 0.0196), FIGO stage (P = 0.0024), or both (P = 0.0047).
FGF18 confers oncogenic effects on ovarian cancer cells in vitro and 
in vivo. To explore the mechanism by which FGF18 overexpression 
modulates ovarian cancer cell biology, we induced ectopic expres-
sion and knocked down FGF18 with lentiviral-based vectors. A224 
and OVCA429 cell lines were selected for overexpression studies 
based on their relatively low endogenous FGF18 expression (Fig-
ure 3, A and B). Cells were transduced with a FGF18-encoding 
lentivirus, or a control lentivirus encoding red fluorescent protein 
(RFP). Overexpression of FGF18 was confirmed by Western blot 
analysis on total cell lysate and conditioned medium produced by 
the infected cells. The functional integrity of ectopically expressed 
FGF18 was confirmed by the increased activation of FRS2 (through 
phosphorylation on tyrosine 196), a pivotal adaptor protein specif-
ic for the signal transduction of FGF receptors (Figure 3B and ref. 
17). Despite minimal effects on cellular proliferation (Supplemen-
tal Figure 5), ectopic FGF18 overexpression significantly increased 
cellular migration and invasion of both A224 and OVCA429 cells 
(Figure 3C). FGF18 is a member of the FGF family of ligands that 
have profound effects on blood vessel formation in physiological 
development (9–11). To test the potential role of FGF18 in angio-
genesis, we investigated the effect of FGF18 on HUVEC motility 
and tube formation. Recombinant human FGF18 (100 ng/ml) pro-
duced a significant chemotactic effect on HUVEC migration (Figure 
3D) and stimulated tube formation by increasing the tube length 
(Supplemental Figure 6A). Similarly, conditioned medium derived 
Figure 2
Validation of the prognostic significance of FGF18 in high-grade, advanced stage serous ovarian cancers through an independent tissue 
microarray (TMA). (A–E) Independent TMA validation of FGF18 expression in 47 benign ovarian cysts and 209 high-grade, late-stage serous 
ovarian cancers. A membrane and cytoplasmic staining pattern was observed for FGF18. Semiquantitative staining intensity evaluation indicated 
significant upregulation of FGF18 in high-grade serous ovarian tumors (C and D) compared with benign ovarian cysts (A and B). Scale bars: 
100 μm. Arrowheads indicate the epithelial layer of the benign ovarian cyst; T and S designate tumor and stromal portions respectively. (F) The 
impact of FGF18 on overall patient survival in the 209 high-grade advanced-stage serous ovarian cancers on the validation TMA. Kaplan-Meier 
analysis was employed with the score of 6 (the highest score of FGF18 in benign ovarian cysts) out of 12 accepted as the cut-off. A statistically 
significant difference was observed indicating a correlation between FGF18 expression and poor prognosis. Black lines, samples with low FGF18; 
red broken lines, samples with high FGF18; +, censored samples.
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from A224 or OVCA429 cells with FGF18 overexpression signifi-
cantly promoted HUVEC migration compared with the conditioned 
medium from RFP control cells (Figure 3D and Supplemental Fig-
ure 6B). Administration of a pan-FGFR inhibitor PD173074 at 
100-nM concentration completely blocked the effect of recombi-
nant FGF18 on HUVEC cells, but only partially blocked the effect of 
conditioned medium from FGF18-overexpressing A224 cells. This 
phenomenon may be due to elevated secretion of other angiogenic 
factors in response to FGF18 overexpression (Figure 3D).
Conversely, inhibition of FGF18 expression by lentivirus-deliv-
ered shRNA (nontargeting scrambled [N/S] shRNA as control) in 
SKOV3 cells (Figure 3E) resulted in no significant difference in 
proliferation (Supplemental Figure 5), but decreased cell migra-
tion and invasion (Figure 3F).
To investigate the effects of FGF18 on ovarian tumor growth in 
vivo, xenograft studies with SCID mice were performed through 
s.c. or i.p. injection. In contrast to RFP-expressing A224 cells that 
failed to develop visible tumor (4-week period for s.c. and i.p.), 
A224 with FGF18 overexpression established robust xenografts 
1 week (s.c.) or 4 weeks (i.p.) after the injection (Figure 4, A and B). 
Similar results were observed with FGF18-overexpressing SKOV3 
cells (Figure 3B and Figure 4C), which showed significantly higher 
xenograft mass in both s.c. (Figure 4A) and i.p. models (average 
weights of i.p. tumors at 4 weeks from 5 mice are 0.26 ± 0.16 g 
Figure 3
Oncogenic effects of FGF18 on ovarian cancer cells in vitro. (A) qRT-PCR analysis of FGF18 from total RNA isolated from 1 normal ovarian surface 
epithelial culture (HOSE), 2 immortalized HOSE cultures (IOSE), and 10 ovarian cancer cell lines. Fold-change is calculated relative to HOSE. (B) 
Ectopic FGF18 or RFP (as control) overexpression by lentiviral vectors. Proper processing and secretion of FGF18 were demonstrated through 
increased phosphorylation of FRS2 and Western blot analysis of the conditioned medium. (C) FGF18 overexpression stimulates migration and inva-
sion in OVCA429 and A224 cells. (D) Recombinant FGF18 (100 ng/ml) and conditioned medium from FGF18-overexpressing A224 cells enhances 
migration of HUVEC cells. To block the effect of FGF18, a pan-FGFR inhibitor PD173074 was used at 100 nM. (E) Ectopic FGF18 knockdown by 2 
lentiviral shRNA constructs that target different regions of FGF18 but not other FGFs. Vector coding an N/S shRNA was used as control. (F) FGF18 
knockdown decreases migration and invasion of SKOV3 cells. *P < 0.05; **P < 0.001. Mean ± SD was from 3 independent experiments.
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Figure 4
Oncogenic effects of FGF18 on ovarian cancer cells in vivo. (A) Ectopic FGF18 overexpression promotes tumorigenicity of ovarian cancer cells 
s.c. inoculated in SCID mice (5 mice in each group; triangles, RFP-overexpressing cells; circles, FGF18-overexpressing cells). (B) FGF18 overex-
pression enables the growth of A224 cells in the i.p. mouse xenograft model (5 mice in each group). Representative photos of xenograft nodules 
(bottom images) are indicated by white arrows. Control RFP-overexpressing cells (top images) failed to develop any visible xenograft during the 
4-week period. Scale bars: 0.5 cm (C) IHC staining of i.p. xenografts derived from SKOV3 cells with FGF18 overexpression and control RFP 
overexpression. Typical sections stained for FGF18, Ki-67, murine CD31, and murine F4/80 were shown. Arrows indicate CD31+ microvessels. 
Quantification of the IHC from 5 mice in each group was presented as well (P < 0.001 in all cases). Scale bars: 25 μm (FGF18); 100 μm (Ki-67, 
CD31, and F4/80) (D) FGF18 knockdown reduces the in vivo tumorigenicity of SKOV3 cells inoculated i.p. in SCID mice (9 mice for N/S shRNA 
as control, 5 mice each for FGF18 shRNA #1 and FGF18 shRNA #2). (E) Pharmacologic inhibition of FGFRs by daily i.p. injection of PD173074 
at a dosage of 25 mg/kg/d significantly retards the i.p. growth of FGF18-overexpressing A224 cells. Vehicle (20% DMSO) served as a control. 
Statistically significant differences were indicated for tumor mass from 5 mice in each group.
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for SKOV3-RFP vs. 3.25 ± 1.37 g for SKOV3-FGF18, P = 0.002). 
Although in vitro proliferation assays showed no significant effect 
of FGF18 on cell growth (Supplemental Figure 5), IHC staining 
of Ki-67 indicated enhanced cell proliferation in FGF18-driven 
xenografts (P < 0.0001, Figure 4C), suggesting a potential role of 
FGF18 in modulating tumor microenvironment. To address this 
issue, microvessel density was measured by IHC staining of murine 
CD31. Consistent with the in vitro observation, increased infiltra-
tion of CD31-positive microvessels in tumor stroma was observed 
in response to increased FGF18 (P = 0.0004, Figure 4C). These 
observations suggest that angiogenesis contributes to the growth 
of xenografts generated by FGF18-overexpressing SKOV3 cells.
Consistently, knockdown of FGF18 in SKOV3 significantly sup-
pressed the growth of i.p. xenografts in SCID mice (P = 0.005, ANOVA) 
(Figure 4D). Compared with N/S shRNA, FGF18 shRNA significantly 
decreased the Ki-67 index, microvessel density, and macro phage infil-
tration in SKOV3-derived xenografts (Supplemental Figure 7).
FGF18 activates multiple signaling events as revealed by expression pro-
filing. To explore the FGF18-mediated downstream events at the 
mechanistic level, we used the Affymetrix Human U133 Plus 2.0 
GeneChip array to perform expression profiling for a series of RNA 
samples isolated from A224 cells overexpressing FGF18 or RFP as 
control in triplicate. A total of 704 probe sets were identified as 
significantly differentially expressed (more than 2-fold, P < 0.001), 
including 3 probe sets for FGF18 showing the largest fold-change 
(Figure 5A and Supplemental Table 4). Changes in transcript lev-
els seen in the microarray data were further validated by qRT-PCR 
on independent RNA samples with primer sets specific for 14 ran-
domly selected genes with different ranges of fold change in A224 
cells (AREG, PLAT, PLAU, HMGA2, CXCL1, CXCL2, IL6, IL8, VEGFC, 
TGM2, CD73, CFH, and CFI) (Figure 5B). Student’s t test showed 
that all 14 genes were differentially expressed (P < 0.01). Further 
validation focused on several FGF18-responsive soluble growth fac-
tors and cytokines due to their known oncogenic roles in ovarian 
Figure 5
Identification of putative FGF18-responsive genes in ovarian cancer cells. (A) Identification of FGF18-responsive genes in A224 cells by comparing 
A224 cells with ectopic overexpression of FGF18 or RFP (as control) through microarray analysis with Affymetrix Human U133 Plus 2.0 chips. (B) 
qRT-PCR validation of randomly selected genes identified in the microarray analysis comparing A224 cells with ectopic overexpression of FGF18 
or RFP. qRT-PCR was performed on 3 independent RNA isolates from the respective cell type and plotted next to the fold-change revealed by 
microarray analysis. (C) Downregulation of FGF18-responsive genes by FGF18 shRNA in SKOV3 cells. N/S shRNA was used as control. Three 
independent RNA isolates were checked by qRT-PCR. Significant change (P < 0.05) was observed in both FGF18 shRNAs for each gene checked.
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tumorigenesis. Significant mRNA upregulation of these genes in 
response to FGF18 overexpression was observed in OVCA429 and 
SKOV3 cells (Supplemental Figure 8). Conversely, decreased expres-
sions of AREG, CXCL1, IL1A, IL6, and IL8 were observed in SKOV3 
cells in response to FGF18 knockdown, supporting that these are 
FGF18-responsive genes in ovarian cancer cells (Figure 5C).
We analyzed the 704 differentially expressed probe sets and 
identified several putative pathways. These included EGF signal-
ing (EREG, AREG), TGF-β signaling (INHBA, TNC), JAK/STAT 
signaling (IL6, IL7, CSF2, IL15RA, HMGA2), NF-κB signaling (IL1A, 
IL8, IRAK2, NFKB2, NFKBIA), and tissue remodeling (PLAT, PLAU, 
PLAUR). Induction of several soluble angiogenic factors such as 
VEGFC, EREG, AREG, CXCL1, CXCL2, CXCL8/IL8, and TNC was also 
discovered by microarray analysis, indicating the potential role of 
FGF18 in modulating the tumor microenvironment and providing 
a reasonable explanation for the observation shown in Figure 3D.
FGFR4 participates in FGF18 signaling in ovarian cancer cells. All 
18 mammalian FGF ligands exert their functions by activating 
1 or more of the 4 distinct cell-surface receptor tyrosine kinases 
(FGFR1–FGFR4) (17). Administration of PD173074, a pan-FGFR 
inhibitor, consistently blocked the FGF18-activated phosphoryla-
tion of FRS2 and Erk1/2 in both A224 and HUVEC cells (Figure 
6A and Supplemental Figure 9). In addition, FGFR blockade by 
PD173074 inhibited FGF18-induced migration and tube forma-
tion in HUVECs (Figure 3D and Supplemental Figure 6A) as well 
as the FGF18-related cytokine production in A224 cells (Figure 
6C). Similarly, i.p. administration of PD173074 at a dosage of 
25 mg/kg/d for 7 days significantly reduced the tumor burden of 
the i.p. xenograft of FGF18-overexpressing A224 cells (Figure 4E).
It has been demonstrated that FGFR4, along with FGFR3c, is a 
receptor for FGF18 (18). We hypothesized that FGFR4 may be an 
important mediator of FGF18 signaling in ovarian cancer patho-
genesis due to physical proximity of the 2 genes within the same 
amplicon along 5q31–5q35.3 (Figure 1C). In A224 cells, activa-
tion of FGFR4 through increased tyrosine phosphorylation was 
observed upon rhFGF18 treatment, which was effectively blocked 
by PD173074 (Figure 6B), indicating the potential involvement of 
FGFR4 in FGF18 signaling. To further validate the receptor speci-
ficity between FGF18 and FGFR4 in A224 cells, we specifically 
“knocked-down” FGFR4 by siRNA (Supplemental Figure 10) and 
observed decreased FGF18 signaling (Figure 6A). FGFR4 siRNA 
also blocked the FGF18-induced cytokine production (Figure 6D). 
Figure 6
Identification of signaling events contributing to the effect of FGF18 on A224 cells. (A) Recombinant human FGF18 activates FRS2 and Erk1/2 
signaling in A224 cells, which can be reversed by pan-FGFR inhibitor PD173074 (50 nM) or siRNA-mediated FGFR4 knockdown (15 nM, 48 
hours pretreatment, N/S siRNA as control). (B) Activation of FGFR4 by treatment of A224 cells with rhFGF18 for 10 minutes. Total cell lysate 
was immunoprecipitated by a phosphorylated-tyrosine antibody 4G10 and immunoblotted with antibodies against total FGFR4, total Erk1/2 (as 
a positive control), and total p38 (as a loading control). (C) Inhibitory effect of pan-FGFR inhibitor PD173074 (100 nM, 48 hours, labeled as PD) 
on the cytokine production in A224 cells overexpressing RFP (white bars) or FGF18 (black bars). Treatment of cells with 0.1 μl/ml of DMSO was 
used as control. (D) Effect of FGFR4 siRNA (15 nM, 48 hours) on the cytokine production in A224 cells overexpressing RFP (empty bars) or 
FGF18 (solid bars). N/S siRNA treatment (15 nM, 48 hours) was used as control. Bar graph represents mean fold change ± SD from 3 indepen-
dent experiments.
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Summation of these results implicates FGFR4 as a mediator of 
FGF18 signaling in serous ovarian cancer cells. The coamplification 
of both the ligand (FGF18) and the receptor (FGFR4) (Figure 1C) 
may contribute to the hyperactivation of FGF signal, mediating the 
5q31–5q35.3 amplicon–related poor patient survival.
FGF18 promotes cytokine production via NF-κB activation. One of the 
most striking features revealed by transcriptome analysis was the 
induction of cytokines and chemokines in response to FGF18 over-
expression. Considering the importance of NF-κB signaling in the 
production of cytokines and chemokines (19) and based on results 
Figure 7
FGF18 as a tumor microenvironment modulator through NF-κB pathway-related cytokine production. (A) Effects of NF-κB pathway inhibition 
on the cytokine production in A224 cells overexpressing RFP (white bars) or FGF18 (black bars). NF-κB pathway inhibitor QNZ (20 nM), SN-50 
(18 μM), or TPCA-1 (1 μM, specifically inhibits IKKβ but not IKKα) was applied for 48 hours. DMSO (0.1 μl/ml) or water (solvent for SN-50, labeled 
as UN) was used as control. (B) Ectopic FGF18 overexpression induces nuclear internalization of NF-κB components p65/Rel-A and p50/NFKB1 
in A224 cells. The purity and loading of each compartment were indicated by GAPDH (cytoplasmic marker) and Histone H3 (nuclear marker). 
(C) FGF18 overexpression enhances the chemotactic effect of A224 cell–derived conditioned medium on monocytic THP-1 cells. Adding 100 
nM PD173074 to harvested conditioned medium shows no significant effect (untreated THP-1 cells used as control unless specified). *P < 0.05; 
**P < 0.001. (D) FGF18 overexpression enhances the M2-polarizing potential of A224 cells. THP-1 cells were cocultured with A224 cells overex-
pressing RFP or FGF18 for 7 days before RNA harvest. qRT-PCR was performed to determine the expression changes of macrophage differentia-
tion markers (for example, IL-10 for oncogenic M2 differentiation, IL-12A for tumor suppressive M1 differentiation) with untreated THP-1 cells as 
control. The THP-1–polarizing potential from RFP- or FGF18-overexpressing A224 cells was compared through the relative fold-change of each 
gene and associated P value (by paired t test). Bar graph represents mean fold change ± SD from 3 independent experiments.
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obtained from microarray data analysis, we hypothesized that NF-κB 
activation may mediate FGF18 downstream events in our system. As 
shown in Figure 7A, application of an NF-κB transactivation inhibi-
tor QNZ reversed FGF18 overexpression-induced upregulation 
of IL-1A, IL-6, IL-8, CXCL1, and CXCL2 in A224 cells. In contrast, 
QNZ failed to inhibit the induction of AREG, a growth factor 
that is not associated with NF-κB signaling (20). Similarly, FGF18 
overexpression-induced cytokine production was also susceptible 
to SN-50 (a competitive substrate against NF-κB nuclear transloca-
tion) and TPCA-1 (an IKKβ inhibitor), indicating the involvement of 
NF-κB dimer translocation and IκB degradation in FGF18-mediated 
NF-κB activation (Figure 7A). Consistently, nuclear internalization 
of the NF-κB component p65/Rel-A and p50/NFKB1 could also be 
observed in A224 cells with FGF18 overexpression (Figure 7B). Taken 
together, these results suggest that FGF18 increases cytokine pro-
duction through the canonical NF-κB pathway.
FGF18 induces the infiltration of monocytes/macrophages and their M2 
polarization. We hypothesized that FGF18 may play a role in modu-
lating the tumor microenvironment through an effect on TAMs 
because the FGF18-responsive cytokines (CXCL1, CXCL2, IL-1, 
IL-6, and IL-8) are strong chemotactic factors for macrophages/
monocytes (21, 22). High TAM infiltration has been linked to 
enhanced metastasis, immunosuppression, angiogenesis and poor 
prognosis in ovarian cancer (23, 24). In the SKOV3 xenograft model, 
Figure 8
FGF18 expression correlates with angiogenic activity and the M2 macrophage infiltration in serous ovarian cancer patients. (A) FGF18 expres-
sion correlates with the numbers of CD31+ microvessels and CD163+ M2-polarized TAM in a cohort of 25 serous ovarian tumor samples. Typical 
staining results from 3 patients were shown. Scale bars: 100 μm. FGF18 was noted to have membrane and cytoplasmic staining under high 
magnification. Scale bar: 25 μm. FGF18 intensity was scored semiquantitatively and plotted as the x axis. The y axis indicates the number of 
CD31+ microvessels or CD163+ TAMs per low power field. Statistical significance was checked by Spearman’s ρ test. (B) Correlation between 
FGF18 and microvessel density in the validation tissue array with 209 high-grade, late-stage serous ovarian cancers. A semi-quantitative grading 
system was used to evaluate CD31 staining in the tissue array. Tissue sections representative of the CD31 grading system (upper panel) and 
corresponding FGF18 staining (lower panel) are shown. Scale bars: 100 μm. Statistical evaluation of the correlation between FGF18 level and 
CD31 score is shown by Spearman’s ρ test on the right.
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M2 macrophages (Figure 7D). Coculture with FGF18-overexpress-
ing A224 cells further potentiated the M2 polarization of THP-1 
cells, as reflected by the additional significant enhancement of the 
M2 characteristic factors tested (Figure 7D). Similar results were 
obtained by comparing the effect on THP-1 differentiation from 
SKOV3 cells with RFP or FGF18 overexpression (Supplemental 
Figure 11). In contrast, directly treating THP-1 cells with rhFGF18 
only showed minimal activation of FGF signaling or induction of 
M2-polarization markers (Supplemental Figure 12). Conversely, 
adding 100 nM PD173074 to the coculture system significantly 
abolished the M2 polarizing potential of FGF18-overexpressing 
A224 cells but not RFP-overexpressing A224 cells (Supplemental 
Figure 13). FGF18 knockdown also ameliorated the M2-polariz-
ing potential of SKOV3 cells (Supplemental Figure 14). Therefore, 
despite posing minimal direct effects, FGF18 is required for the 
M2-polarizing potential of ovarian tumor cells. Taken together, 
through the accumulation and polarization of TAMs, elevated 
FGF18 in ovarian tumor cells potentiates dynamic changes in the 
tumor microenvironment and promotes tumor progression.
FGF18 expression is significantly correlated with microvessel density and 
TAM infiltration in serous ovarian cancer. Given the pronounced biologic 
effect of FGF18 on the tumor microenvironment, we hypothesized 
that elevated FGF18 expression might be associated with enhanced 
angiogenesis and TAM infiltration in tumors from ovarian cancer 
patients. IHC staining was performed on FFPE samples of 25 high-
grade, late-stage serous ovarian cancers with antibodies against 
FGF18, CD31 (marker of microvessels), and CD163 (marker of 
M2-polarized macrophages) (Figure 8A). Statistically significant cor-
relations were obtained between FGF18 expression and the presence 
of CD31+ microvessels and CD163+ M2 TAMs (P < 0.0001 in both 
cases). Furthermore, IHC staining of a tissue microarray with 209 
serous ovarian cancers revealed a similar correlation between FGF18 
concentration and CD31+ microvessel density (P < 0.0001) (Figure 
8B). These data suggest that FGF18 modulates tumor microenvi-
ronment by promoting neovascularization as well as recruitment of 
M2-polarized TAMs in serous ovarian cancer patients.
Discussion
In this study, we provided mechanistic evidence in vitro and in 
vivo to delineate the oncogenic role of FGF18 in serous ovarian 
cancer as a prognostic and therapeutic biomarker. By combining 
our previous CGH work with gene expression profiling in high-
grade serous ovarian tumor samples, we have identified FGF18 
as an independent survival-associated gene contributing to the 
prognostic impact of 5q31–5q35.3 amplicon. In addition to gene 
amplification, our IHC study demonstrated FGF18 overexpression 
in approximately 50% of high-grade serous tumor cases compared 
with benign cysts (Figure 2, A–E). We therefore expect additional 
transcriptional or posttranscriptional mechanisms to contribute 
to elevated FGF18 in serous ovarian cancers. Although the detailed 
mechanism is still unknown, it has been demonstrated physiologi-
cally that FGF18 expression can be upregulated by intracellular cal-
cium signaling (25), which is also frequently hyperactivated in neo-
plastic contexts. Second, FGF18 was mainly observed in epithelial 
tumor cells rather than the stromal component in our IHC studies. 
However, we did find cases showing substantial positivity in tumor 
stroma, indicating the potential contribution from stroma-derived 
FGF18 to ovarian tumorigenesis through paracrine release.
Functionally, FGF18 regulates both tumor cells and tumor micro-
environment to facilitate the progression of serous ovarian cancer. 
FGF18 overexpression produced a tumor stroma greatly enriched 
with TAMs (determined by murine TAM marker F4/80, Figure 4C, 
P = 0.007), while FGF18 knockdown significantly reduced the 
murine macrophage infiltration (Supplemental Figure 7). Consis-
tently, conditioned medium from A224 cells with FGF18 overexpres-
sion also showed significantly higher chemotactic effect on mono-
cytic leukemia cell line THP-1 in a Boyden chamber assay compared 
with the conditioned medium from control RFP-overexpressing cells 
(Figure 7C). Addition of 100 nM PD173074 after harvest showed no 
significant impact on the chemotactic potential of the conditioned 
medium from either RFP- or FGF18-overexpressing cells, indicating 
that enhanced THP-1 migration was dependent on FGF18-induced 
soluble factors rather than the secreted FGF18 itself.
Once recruited to the tumor tissue, monocytic cells undergo 
differentiation and mature as M2 macrophages under the influ-
ence of tumor cells. The M2 polarization is generally accompanied 
by the production of trophic and angiogenic growth factors (for 
example, VEGF, IL-8, IL-1, CXCL1, and CCL2), ECM degrading 
proteases (for example, MMP2 and MMP9), and immunosuppres-
sors (for example, IL-10 and downregulation of IL-12) by the TAMs 
to provide a microenvironment conducive to tumor growth and 
angiogenesis. This was demonstrated by coculture of THP-1 cells 
with RFP-overexpressing A224 cells in a Transwell system, which 
triggered the differentiation of THP-1 cells into TAM-like cells 
that displayed the above-mentioned phenotypic characteristics of 
Figure 9
The effect of FGF18 on the pathogenesis of serous ovarian cancer. 
Genes directly or indirectly induced by FGF18 are labeled in red. Arrows 
indicate potential interactions that contribute to FGF18-mediated 
ovarian tumorigenesis. Solid arrows, direct effects; dashed arrows, indi-
rect effects; broken arrows, secretion; blue lines, binding.
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vasculature and TAMs, considering the prominent physiologic 
effect of FGF18 on cells with mesenchymal origin (for example in 
osteogenesis, chondrogenesis, and alveologenesis), future studies 
may also need to explore the effects of FGF18 on tumor-associated 
fibroblasts, another important player in the progression of serous 
ovarian cancer (38). In fact, recent studies have demonstrated that 
FGF18-related proinflammatory cytokines and chemokines, such 
as CXCL1, are capable of transforming tumor-associated fibro-
blasts to a “senescence associated secretory phenotype,” which in 
turn becomes another important source of soluble factors for tumor 
growth, metastasis, and angiogenesis (39, 40). In summary, we pro-
pose that the aberrant upregulation of FGF18 in ovarian cancer cells 
may initiate reciprocal heterotypic signaling interactions and cas-
cades in neoplastic cells and nonneoplastic cells within the tumor 
microenvironment and eventually accelerate the malignant progres-
sion to convey a poor outcome in serous ovarian cancer (Figure 9).
In this study, we identified the unique correlation between FGF18 
overexpression and patient survival among the human FGF ligands 
and receptors in serous ovarian cancer (Table 1). Other candidate 
ovarian cancer–related FGF/FGFR genes identified so far include 
FGF1 (4), FGF2, FGF7, FGF8 (overexpression, prognostic value 
unknown) (41), and FGFR4 (42). Unlike FGF18, which shows aber-
rant upregulation and independent prognostic impact in multiple 
data sets, these FGF/FGFR associations are based on single-patient 
cohorts without cross-validation. In this report, we demonstrated 
the ability of FGFR4 to mediate FGF18 signaling and its biologic 
activity by activating MAPK/ERK and NF-κB. However, FGFR4 
alone failed to show any significant tumor-related upregulation or 
patient survival correlation in all 3 data sets investigated in this 
study (refs. 3, 5, 6, and Table 1). One potential explanation is that 
the function (and impact) of FGFR4 is ligand dependent. Overex-
pression of FGFR4 itself may not directly contribute to ovarian 
tumorigenesis without activation from high levels of ligands (most 
commonly FGF18). This would occur most possibly from coam-
plification. However, other sources of FGF18 from transcriptional 
deregulation could also provide neoplastic signaling. Considering 
the rare activating mutation rate of FGF receptors in ovarian can-
cer (43), the previously observed prognostic power of FGFR4 (42) 
may be dependent on the coexpression of prognosis-defining FGF 
ligands such as FGF18. Conversely, neoplastic signaling could be 
conveyed by the presence of increased ligand (FGF18) without sig-
nificant alteration in the expression level of the receptor (FGFR4). 
This point is especially important for 5q31–5q35.3 amplicon void 
cancers, in which the coexpression of FGFR4 and FGF18 cannot be 
achieved by coamplification.
Our initial analysis of the 5q31–5q35.3 amplicon suggested 
FGF1 was a driver based on its biology (4, 42). This analysis has 
provided important data to further refine the role of FGF ligands 
and their receptors in the development and progression of ovar-
ian cancer. Nevertheless, FGF1 was not differentially expressed 
between normal and serous tumor tissue (Table 1; in TCGA data 
set [ref. 6], 1.02-fold, P = 0.77; in data set of Wu et al. [ref. 12], 1.05-
fold, P = 0.27). FGF1 does also activate FGFR4 and increase the 
activating phosphorylation of p65/Rel-A at Ser536 (42), but it is 
not clear whether any of the biologic impacts or downstream sig-
nature is mediated through these events. We thus believe FGF18 
is the predominant ligand contributing to the biology of clinical 
outcome described here, although it is conceivable that there are 
selected tumors in which FGF1 is coamplified and expressed where 
it contributes to the biology along with FGF18. Taken together, we 
In agreement with our in vitro and in vivo data, correlation between 
FGF18 expression level and clinicopathological features such as 
microvessel density, tumor-associated macrophage infiltration, 
and overall patient survival further validated its prognostic value. In 
addition, pathway analysis also suggested a systematic contribution 
from deregulated FGF18 to the aberrant signaling pathways respon-
sible for the malignancy. Of the 7 signaling pathways summarized 
as activated in greater than 50% of ovarian cancers (2), 3 overlap with 
the potential FGF18 downstream signals. These pathways include 
MAPK/ERK (FGF18/FGFR, EREG/EGFR, or AREG/EGFR), IL-6R/
JAK/STAT (IL6, IL7, IL15RA, and HMGA2), and NF-κB. Further-
more, FGF18-induced upregulation of FZD10, JAG1, HES1, SOX9, 
and HMGA2 in A224 cells may also indicate a possible relationship 
between FGF18 signaling and Wnt, Notch, Hedgehog, and epithelial- 
mesenchymal transition pathways (26, 27).
Activation of NF-κB pathway has been shown to be crucial for the 
progression of ovarian cancer (28). In this study, we have demon-
strated that FGF18-driven NF-κB activation upregulates various 
proinflammatory cytokines and chemokines including IL-1, IL-6, 
IL-8, CXCL1, and CXCL2 to provide a microenvironment for tumor 
growth (reviewed in refs. 29, 30). Canonical NF-κB activation by 
IKKβ was also shown and is likely stimulated by upstream signal-
ing such as MAPK/ERK, initiated by FGF18 (31). Additionally, the 
FGF18-mediated upregulation of HMGA1 and HMGA2 (Supple-
mental Table 4, Figure 5, and Supplemental Figure 8) as DNA-bind-
ing adaptor and NF-κB transactivation enhancer (32–34) may also 
contribute to the enhanced NF-κB activity in response to FGF18 
overexpression and will require further investigation.
Besides direct action in ovarian tumor cells, FGF18-mediated 
events also directly or indirectly modulate the stroma, in particular 
the vasculature and TAMs, to facilitate the colonization and expan-
sion of tumor cells. Expansion and metastasis of ovarian cancer 
requires angiogenesis to provide oxygen, other essential nutrients, 
and possible routes for local and distant dissemination. In addi-
tion, the proinflammatory state and corresponding infiltration of 
TAMs has been shown to be influenced by paracrine signaling at 
multiple steps of tumor progression and neoplastic angiogenesis 
(23, 24). Our study revealed an FGF18-mediated orchestration, with 
contributions from both tumor and stromal cells, that modulates 
the profile of secretory molecules in the neoplastic microenviron-
ment. These molecules include growth factors (AREG, EREG) (35), 
proangiogenic growth factors (VEGFA, VEGFC, IL-1, IL-8, CCL2, 
CXCL1, CXCL2), proangiogenic matrix proteins (TNC, SEMA3C, 
NRP2), proangiogenic/proinvasive matrix-degrading enzymes 
(MMP9, MMP2, PLAT, PLAU), and cytokines and chemokines that 
mediate inflammatory response (CCL2, CXCL1, IL-1, IL-6, IL-8) 
and immunotolerance (CCL2, IL-6, IL-10, and downregulation of 
IL-12). In our xenograft model, A224 grew no tumors in the absence 
of ectopic FGF18 overexpression. The supportive effect of FGF18 
on the in vivo tumor growth in FGF18-overexpressing A224 cells 
has been confirmed by PD174074-mediated tumor inhibition of 
already established i.p. xenografts (Figure 4E). However, considering 
that enhanced proliferation or angiogenesis only applies to estab-
lished tumor masses, regulation of tumor engraftment efficiency 
may also contribute to FGF18-mediated tumorigenicity. Recently, 
tumor-associated macrophages have been demonstrated vital for 
efficient de novo tumor engraftment (36, 37). Therefore, the mac-
rophage recruitment and toning by FGF18 as shown in this study 
may also potentially contribute to tumor implanting and estab-
lishment, clearly worth further investigation. In addition to tumor 
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autoclave for 12 minutes (for FGF18 antibody) or in a 100°C waterbath 
for 30 minutes (for all the other antibodies). Primary antibodies against 
human FGF18 (1:30), CD31 (marker of endothelial cells, 1:50), and CD163 
(marker of M2 differentiated macrophages, 1:100), diluted in DAKO anti-
body diluent, were applied to sections and incubated in a humidified 
chamber at room temperature for 1 hour. Antigen visualization was per-
formed with ImmPRESS Peroxidase Polymer Detection Reagents (Vector 
Laboratories) and 3,3′-diaminobenzidine (DAB), followed by counterstain-
ing with Mayer’s hematoxylin (Sigma-Aldrich). A negative same-species 
IgG control was included in every experiment.
FGF18 protein expression grading was conducted by determining the 
percentage and intensity of positive cells in 3 different areas at low-power 
(×100) magnification. First, the percentage of positive cells in each section 
was scored with a 5-point scale: 0 for <5%, 1 for 5%–25%, 2 for 26%–50%, 
3 for 50%–75%, and 4 for over 75%. Second, the intensity of positive signal 
was scored with a 3-point scale: 1 for weak staining, 2 for moderate stain-
ing, and 3 for intense staining. The weighed score of FGF18 staining inten-
sity of each section was obtained by multiplying the percentage score by 
the intensity score (the maximum weighed score is 12). Microvessel density 
was evaluated based on Weidner’s method (45) by averaging the number of 
microvessels found in 5 selected ×100 fields showing the strongest CD31 
positivity. Each CD31+ endothelial cell cluster was counted as an individual 
vessel in addition to the morphologically identifiable vessels with a lumen. 
The infiltration of M2 macrophages was assessed by counting the num-
ber of CD163+ cells in 5 selected ×100 fields where the most staining was 
observed. A semiquantitative grading method was used for the evaluation 
of angiogenesis activity in the tissue microarray (Figure 8B). The number 
of microvessels was estimated in 3 low-power fields for each sample and 
the average was taken to determine the CD31 grade as follows: grade 1: 
number of CD31+ microvessels is less than 15; grade 2: number of CD31+ 
microvessels is 15–50; grade 3: number of CD31+ microvessels is greater 
than 50; grade 4: clusters of microvessels observed, CD31+ area is greater 
than 30% of the field.
The IHC was performed by 2 individuals, including 1 pathologist for 
independent IHC scoring. The scoring was done blinded to the clinical data.
IHC staining of the FFPE xenograft sections was performed with the 
same protocol as that used for the staining of patient samples. Dilution 
rates of primary antibodies against FGF18, Ki-67, CD31, and F4/80 (for 
TAM infiltration) were optimized as 1:30, 1:100, 1:200, and 1:50, respec-
tively. Antigens were visualized by corresponding ImmPRESS anti-mouse/
rabbit, anti-goat, or anti-rat Ig HRP systems (Vector Labs) with DAB as 
substrate and counterstained with Mayer’s hematoxylin. Staining evalua-
tion was performed in the same way as for patient samples.
Gene expression manipulation. Ectopic overexpression and knockdown of 
FGF18 were performed by lentiviral vector-mediated delivery of FGF18 
cDNA (pLoc series) or microRNA-adapted shRNA (pGIPZ series) against 
FGF18. Prevalidated plasmid constructs, control plasmids, and lentiviral 
packaging system were purchased from Thermo Scientific. 293FT cells and 
Lipofectamine 2000 for viral production were purchased from Invitrogen. 
Viral supernatants were harvested 48 hours and 72 hours after transfec-
tion, filtered through a 0.45-μm PVDF filter, titrated with 293FT cells, and 
stored in a –80°C freezer. Ovarian cancer cells A224, OVCA429 (for overex-
pression), and SKOV3 (for overexpression and knockdown) were infected 
at an MOI of 3–10. Stably infected cells were maintained in medium con-
taining blasticidin S (for overexpression) or puromycin (for knockdown).
Knockdown of FGFR4 was achieved by transfecting 15 nM of siRNA 
against FGFR4 for 48 hours. FGFR4 siRNA, N/S siRNA, and HiPerFect 
Transfection Reagent were purchased from QIAGEN.
Statistics. Statistical analysis was performed with SPSS 17.0 software 
(SPSS Inc). Kaplan-Meier analysis (with the P value of log-rank test shown 
conclude the FGF18 overexpression–induced hyperactivation of 
FGF signaling may be one of the mechanisms defining the prog-
nostic power of 5q31–5q35.3 in ovarian cancer patients. Therefore, 
blocking FGF signaling becomes a rational therapeutic approach 
for ovarian cancer patients with 5q31–5q35.3 amplification. Eval-
uation of large-scale patient cohorts is currently ongoing to estab-
lish the potential correlation between 5q31–5q35.3 amplification 
and specific FGF pathway activation.
So far, several therapeutic approaches against FGF signaling 
have been developed, including receptor tyrosine kinase inhibi-
tors, receptor-neutralizing antibodies, and FGF ligand traps (17, 
43, 44). In fact, we have demonstrated the feasibility of FGF18 tar-
geting by using pan-FGFR inhibitor PD173074 in an orthotropic 
mouse model (Figure 4E). However, long-term blockade of FGF 
receptors by either small molecules or antibodies has been dem-
onstrated toxic through “on-target” (for example through FGFR4, 
the receptor for homeostasis related FGF19 and FGF23) induced 
hyperphosphatemia and renal failure in human clinical trials (44). 
The alternative approach of identifying and blocking the appro-
priate FGF ligand thus becomes a more feasible strategy. One of 
such reagents is the soluble decoy receptor FP-1039, which neu-
tralizes multiple FGF ligands based on their affinity to FGFR1c. 
Interestingly, the antitumor response of FP-1039 has been shown 
to be positively correlated with the FGF18 RNA level in a panel of 
39 tumor cell lines (44). Although ovarian cancer cell lines were 
not investigated in the above study, we expect substantial targeting 
efficacy of FP-1039 in the context of ovarian cancer. The progres-
sion of ovarian cancer involves a complex network of biological 
processes; targeting a versatile gene such as FGF18 which affects 
both tumor cells and genomically stable tumor stromal cells may 
improve therapeutic response. Subsequent work will be needed to 
confirm the prognostic value of FGF18 in larger groups of patients 
and identify individuals suitable for FGF targeted therapy.
Methods
Reagents and biological samples. The 53 microdissected, high-grade advanced-
stage serous ovarian adenocarcinoma samples for the expression profiling 
have been described previously (5). The 25 high-grade, late-stage, serous 
ovarian tissue specimens used to investigate the potential correlation 
between FGF18 and microvessels or TAM infiltration were available FFPE 
samples from the CGH study (16). A validation tissue microarray was con-
structed with 263 FFPE samples obtained from patients with informed 
consent at the MGH between 1993 and 2009. This tissue microarray 
included 47 serous cystadenomas (benign cyst) and 216 FIGO stage III/
IV high-grade serous ovarian cancers (selected to have >80% tumor tissue 
and <20% stroma and necrosis). Overall survival information was avail-
able for 209 samples, which were used to determine the impact of FGF18 
expression on patient prognosis. For IHC staining, all FFPE tissues or 
tissue arrays were cut into 7-μm sections on Superfrost/Plus slides (Fisher 
Scientific). All specimens and their corresponding clinical information 
were collected under protocols approved by the Institutional Review 
Boards of the MGH.
Gene expression profiles and related clinicopathological data were 
obtained from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) (3, 5, 12–14) and the Cancer Genome Atlas Data Portal (https:// 
tcga-data.nci.nih.gov) (6).
Details of cell lines, antibodies and chemical reagents used in this study 
are described in the Supplemental Methods.
Immunohistochemistry. Antigen retrieval for FFPE sections was achieved by 
heating the slides in 0.01 M citrate buffer (pH 6.1, DAKO) in a 121°C, 15 psi 
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by the MGH Subcommittee on Research Animal Care in accordance with 
the NIH Guideline for Laboratory Animals.
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